NCT01320280View on ClinicalTrials.gov

BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer

PHASE2TerminatedINTERVENTIONAL

Enrollment

29

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Refractory Cancer

Interventions

DRUG

BIBW 2992 (Afatinib)

50 mg BIBW 2992 (Afatinib) tablets daily continuously

Trial Locations (1)

20246

University Medical Center Hamburg-Eppendorf, Hamburg

Sponsors

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

Boehringer Ingelheim

INDUSTRY

lead

Universitätsklinikum Hamburg-Eppendorf

OTHER